Price movement over the last 24 hours
Global X MSCI Argentina ETF vs Medtronic PLC — how do they compare? Global X MSCI Argentina ETF trades at $95.07, while Medtronic PLC trades at $84.19 (market cap $107.36B). The key difference: Medtronic PLC pays a 3.43% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| ARGT | MDT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $105.35 |
52-Week Low | $67.55 | $73.75 |
Market Cap | — | $107.36B |
Enterprise Value | — | $126.10B |
Dividend Yield | — | 3.43% |
Signals from Pluang's Aura AI — not financial advice
ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.
The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.
Medtronic (MDT) trades at $83.87, up 1.8% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats with Q1 2026 EPS of $1.55 exceeding expectations, while revenue growth accelerated to $33.54B in 2025. Analyst consensus remains strongly positive with 58% buy ratings and a $97.31 price target, representing 16% upside potential from current levels.
MDT presents an attractive investment case with solid profitability metrics, dividend aristocrat status, and accelerating revenue growth. Key risks include increasing debt levels (debt-to-asset ratio rose to 31.11% in 2025) and margin pressure from tariffs. The company's strategic acquisitions and innovation in cardiovascular and neuroscience segments support long-term growth prospects despite near-term headwinds.
Trailing returns across standard periods
Latest headlines on both assets
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →